Skip to content

5 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Molecular landscape of anaplastic transformation in pancreatic ductal adenocarcinoma.

Pancreatic ductal adenocarcinoma (PDAC) with anaplastic features is a rare and highly aggressive subtype with an extremely poor prognosis. However, the molecular mechanisms underlying anaplastic transformation remain poorly understood. To characterize the anaplastic transformation molecular landscape, we analyzed genom...

Akimasa Hayashi, Shota Sasagawa, Takahiro Shibayama et al. · 0 citations
Sep 2026

Abstract B020: Myofibroblasts induce neuroplasticity to promote pancreatic inflammation and cancer progression

Beyond direct epithelial effects, sympathetic nerves promote pancreatitis and PDAC by co-opting myofibroblasts and myCAFs as disease amplifiers, highlighting CAF subtype–specific stromal interactions as putative therapeutic targets.

Jérémy Nigri, Wen-Jun Lan, M.-L. Fung et al. · 0 citations
Review Sep 2026

Abstract A042: ctDNA KRAS detection in pancreatic ductal adenocarcinoma: Platform concordance, sensitivity and clinical associations in a contemporary cohort

Multiple circulating tumor DNA (ctDNA) platforms are available for KRAS mutation detection in pancreatic ductal adenocarcinoma (PDAC), including broad next-generation sequencing (NGS) and targeted quantitative polymerase chain reaction (qPCR) assays, yet comparisons of performance and concordance are limited. We...

Jennifer Guo, Michael S. May, Michael F. Berger et al. · 0 citations
Open access Sep 2026

Neoantigen-reactive CD8+ T cell engagement marks exceptional survivors of pancreatic cancer

Pancreatic cancer (PC) is largely refractory to immune checkpoint blockade (ICB), although homologous recombination-deficient (HRD) tumors may derive benefit. In the POLAR trial of maintenance pembrolizumab plus olaparib after platinum-based chemotherapy for metastatic PC, responses remained heterogeneous. To define de...

M. Hilmi, J. Schoenfeld, Wilson H. McKerrow et al. · 0 citations
Sep 2026

Abstract PR014: Integrated translational analyses of the first generation KRAS G12D degrader setidegrasib identify mechanisms of response and resistance and offers rational combination strategies in pancreatic cancer

KRAS G12D is a prevalent oncogenic driver in PDAC, which has a high unmet need due to few effective targeted therapies. Setidegrasib, a novel KRAS G12D-targeted protein degrader, eliminates the oncogenic driver to suppress downstream signaling and induce tumor cell death. Early clinical activity was reported in a...

W. Park, S. Kadam, A. Kasi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.